Core Viewpoint - MIRA Pharmaceuticals is advancing its novel oral ketamine analog, Ketamir-2, in collaboration with Memorial Sloan Kettering Cancer Center to evaluate its effectiveness in managing cancer pain and associated depression [1][2][4]. Company Overview - MIRA Pharmaceuticals is a pre-clinical-stage pharmaceutical company focused on neurologic and neuropsychiatric disorders, holding exclusive rights for Ketamir-2 in the U.S., Canada, and Mexico [9]. - The company is also developing MIRA-55, a novel oral pharmaceutical marijuana for treating anxiety and cognitive decline [10]. Collaboration with Memorial Sloan Kettering - The partnership with MSK aims to validate Ketamir-2's potential and broaden its applications beyond treatment-resistant depression and PTSD [2][4]. - MSK currently uses intravenous ketamine for refractory cancer pain, and the oral formulation of Ketamir-2 could offer a safer, more convenient alternative [3][5]. Clinical Development and Market Potential - The collaboration will assess Ketamir-2's efficacy in a rodent model for cancer pain, potentially streamlining the regulatory approval process for clinical trials [6]. - Successful preclinical outcomes could accelerate the FDA approval pathway for Ketamir-2, enhancing MIRA's capacity to deliver innovative treatments [6]. Cancer Pain Statistics - Approximately 44% of cancer patients experience pain, with 31% suffering from moderate to severe pain [8]. - Around 25% of cancer patients also suffer from depression, significantly higher than the general population [8].
MIRA Pharmaceuticals in Discussions with Memorial Sloan Kettering to Collaborate on Preclinical Cancer Pain Model Utilizing The Company's Novel Oral Ketamine Analog